TacticScaleWhat Intuitive Surgical Does & How It Makes Money (ISRG)
Updated October 2026 · reflects Intuitive Surgical's latest reported financials
Maker of da Vinci robotic surgery systems and Ion lung-biopsy platform. It sells da Vinci and Ion systems to hospitals through direct capital and clinical sales teams.
How Intuitive Surgical makes money
It sells da Vinci and Ion systems to hospitals through direct capital and clinical sales teams. It also earns money from the stapling, energy, and core instruments used with the systems, plus services such as installation, repair, maintenance, technical support, and digital tools.
What Intuitive Surgical does
Intuitive Surgical, founded in 1995 and based in Sunnyvale, California, is known for the da Vinci Surgical System, a robotic platform that lets surgeons operate through small incisions. The aim is to make minimally invasive care better and easier to get, for patients in the United States and abroad. With its Ion endoluminal system, the company has moved beyond surgery into diagnosis: Ion helps doctors perform minimally invasive biopsies deep in the lung. The business goes well beyond selling machines. Around its multi-port da Vinci systems, Intuitive supplies stapling, energy, and core instruments, along with training pathways for surgeons. It also offers installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring, and its connected digital tools give hospitals insights to improve their surgical programs. Direct capital and clinical sales teams sell all of this to hospitals and other healthcare providers.
Products & services
- da Vinci Surgical System
- Ion endoluminal system
- da Vinci stapling and energy instruments
- Surgeon training and learning pathways
- System service, repair and 24/7 technical support
- Connected digital hospital insights
What is Intuitive Surgical worth?
On an owner-earnings DCF, Intuitive Surgical's most-likely value is about $407 versus a recent price near $426 (4% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$105) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Integra LifeSciences (IART) · LivaNova (LIVN) · ICU Medical (ICUI) · Artivion (AORT)